The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity

Autor: Mark F. Maurer, Katherine E. Lewis, Joseph L. Kuijper, Dan Ardourel, Chelsea J. Gudgeon, Siddarth Chandrasekaran, Sherri L. Mudri, Kayla N. Kleist, Chris Navas, Martin F. Wolfson, Mark W. Rixon, Ryan Swanson, Stacey R. Dillon, Steven D. Levin, Yengo Raymond Kimbung, Masato Akutsu, Derek T. Logan, Björn Walse, Kristine M. Swiderek, Stanford L. Peng

Publikováno v: Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)

CD28 costimulatory signalling can be suppressed by immune checkpoints, such as CTLA-4 and PD-1. Here the authors describe the design of the fusion therapeutic davoceticept (ALPN-202), based on a variant CD80 extracellular domain engineered to bind PD

Externí odkaz: https://doaj.org/article/1c1e0e459c4147429eef80ef95841f04

Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

Autor: Luuk Wieske, Koos P J van Dam, Maurice Steenhuis, Eileen W Stalman, Laura Y L Kummer, Zoé L E van Kempen, Joep Killestein, Adriaan G Volkers, Sander W Tas, Laura Boekel, Gerrit J Wolbink, Anneke J van der Kooi, Joost Raaphorst, Mark Löwenberg, R Bart Takkenberg, Geert R A M D'Haens, Phyllis I Spuls, Marcel W Bekkenk, Annelie H Musters, Nicoline F Post, Angela L Bosma, Marc L Hilhorst, Yosta Vegting, Frederike J Bemelman, Alexandre E Voskuyl, Bo Broens, Agner Parra Sanchez, Cécile A C M van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J G M Verschuuren, Annabel M Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Renée C F Allaart, Y K Onno Teng, Pieter van Paassen, Matthias H Busch, Papay B P Jallah, Esther Brusse, Pieter A van Doorn, Adája E Baars, Dirk Jan Hijnen, Corine R G Schreurs, W Ludo van der Pol, H Stephan Goedee, Sofie Keijzer, Jim B D Keijser, Arend Boogaard, Olvi Cristianawati, Anja ten Brinke, Niels J M Verstegen, Koos A H Zwinderman, S Marieke van Ham, Taco W Kuijpers, Theo Rispens, Filip Eftimov, R. de Jongh, C.E. van de Sandt, L. Kuijper, M. Duurland, R.R. Hagen, J. van den Dijssel, C. Kreher, A. Bos, V. Palomares Cabeza, V.A.L. Konijn, G. Elias, J.G. Vallejo, M.J. van Gils, T.M. Ashhurst, S. Nejentsev, E.S. Mirfazeli

Publikováno v: The Lancet Rheumatology, 4(5), e338-e350. Elsevier
The Lancet. Rheumatology, 4(5), e338-e350. Elsevier Ltd
The Lancet Rheumatology, 4(5), E338-E350. ELSEVIER
T2B! immunity against SARS-CoV-2 study group 2022, ' Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants : a cohort study ', The Lancet Rheumatology, vol. 4, no. 5, pp. e338-e350 . https://doi.org/10.1016/S2665-9913(22)00034-0
The Lancet Rheumatology, 4(5), e338-e350. Lancet Publishing Group
The Lancet Rheumatology, 4(5), E338-E350. Lancet Publishing Group

Background: Disease-specific studies have reported impaired humoral responses after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders treated with specific immunosuppressants. Disease-overarching studies, and data on reca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32cd7639bd3c42720d60a555471f4e04
https://pubmed.ncbi.nlm.nih.gov/35317410

Abstract 1740: Engineered variant domain fusion proteins provide checkpoint inhibition and tumor antigen dependent CD28 costimulation resulting in potent anti-tumor immunity

Autor: Siddarth Chandrasekaran, Demonte Daniel William, Logan Garrett, Stanford L. Peng, Ardourel Daniel F, Katherine E. Lewis, Sherri Mudri, Mark F. Maurer, Kayla N. Kleist, Michelle A. Seaberg, Jing Yang, Steven D. Levin, Mark W. Rixon, Joseph L. Kuijper, Rachel Wang, Stacey R. Dillon, Hieu Nguyen, Chelsea J. Gudgeon, Martin F. Wolfson

Publikováno v: Cancer Research. 81:1740-1740

Introduction: Checkpoint inhibition (CPI) has been shown to be an effective anti-tumor therapy, but CPI alone is frequently insufficient to control tumor growth, and costimulatory signals may also be required to produce clinically significant anti-tu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ad26d42c81f0996e63429f20a500526e
https://doi.org/10.1158/1538-7445.am2021-1740

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Abstract 4550: CD80 vIgD-Fc proteins combine checkpoint antagonism and costimulatory signaling for potent antitumor immunity

Autor: Stacey R. Dillon, Ryan Swanson, Steve D. Levin, Martin F. Wolfson, Mark F. Maurer, Chelsea J. Gudgeon, Chris L. Navas, Joseph L. Kuijper, Katherine E. Lewis, Michael Kornacker

Publikováno v: Cancer Research. 78:4550-4550

Introduction: PD-1 pathway antagonists have revealed the importance of checkpoint pathways in regulating antitumor immunity, but an existing immune response is generally required for clinical efficacy. Specific T cell costimulation through CD28 is ce

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7b8eea358913e2c204111044461c5dd5
https://doi.org/10.1158/1538-7445.am2018-4550